Direct oral anticoagulants versus Vitamin K antagonists for left ventricular thrombus management

Area of Science:

• Cardiology
• Pharmacology
• Clinical Research

Background:

• Left ventricular thrombus (LVT) management often involves anticoagulation therapy.
• Direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) are common anticoagulant choices.
• Comparative safety data for DOACs versus VKAs in LVT management is crucial.

Purpose of the Study:

• To compare the incidence of intracranial hemorrhage (ICH), ischemic stroke, transient ischemic attack (TIA), and major bleeding events.
• To evaluate the safety profiles of DOACs versus VKAs in patients with LVT.
• To assess outcomes at 12 and 24 months post-treatment initiation.

Main Methods:

• Retrospective analysis of claims data involving 3152 patients treated for LVT.
• Exact matching of two cohorts based on age, sex, and comorbidities.
• Kaplan-Meier method used to assess differences in primary outcomes (ICH, ischemic stroke, TIA, major bleeding) at 12 and 24 months.

Main Results:

• A matched cohort of 336 patients (168 per group) was analyzed.
• No statistically significant differences were observed in the rates of ICH, ischemic stroke, TIA, or major bleeding events between DOAC and VKA groups at 12 months.
• Similar findings of no significant differences in these adverse events were noted at 24 months between the two anticoagulant groups.

Conclusions:

• Direct oral anticoagulants (DOACs) appear to be safe and effective alternatives to vitamin K antagonists (VKAs) for left ventricular thrombus (LVT) management.
• The findings support the use of DOACs in clinical practice for LVT patients.
• Further prospective studies are warranted to confirm these safety and efficacy outcomes.